Valuation: Ironwood Pharmaceuticals, Inc.

Market Cap 683M 592M 552M 507M 958M 64.96B 968M 6.48B 2.54B 32.5B 2.57B 2.51B 108B P/E 2026 *
3.5x
P/E 2027 * 3.36x
Enterprise Value 683M 592M 552M 507M 958M 64.96B 968M 6.48B 2.54B 32.5B 2.57B 2.51B 108B EV / Sales 2026 *
1.48x
EV / Sales 2027 * 1.43x
Free-Float
96.75%
Yield 2026 *
-
Yield 2027 * -
1 day-3.71%
1 week+16.57%
Current month-1.89%
1 month-4.16%
3 months-11.13%
6 months-6.74%
Current year+23.15%
1 week 3.87
Extreme 3.87
4.59
1 month 3.55
Extreme 3.55
4.88
Current year 2.95
Extreme 2.95
5.78
1 year 0.81
Extreme 0.81
5.78
3 years 0.53
Extreme 0.5271
15.7
5 years 0.53
Extreme 0.5271
15.7
10 years 0.53
Extreme 0.5271
21.2
Manager TitleAgeSince
Chief Executive Officer 68 11/03/2021
Director of Finance/CFO 44 14/05/2026
Chief Tech/Sci/R&D Officer - 19/07/2026
Director TitleAgeSince
Director/Board Member 68 03/06/2021
Chairman 61 31/03/2019
Director/Board Member 56 31/03/2019
Date Insider Type Main position Quantity % Market Cap.
20/07/26 Free

Chief Technology Officer

137,036 0.0832%
07/07/26 Sell

Chief Financial Officer

-127,890 0.0777%
23/02/26 Sell

Chief Executive Officer

198,283 0.1219%
Change 5-day change 1-year change 3-year change Capi.($)
-3.71%+16.57%+415.78%-62.71% 683M
+0.26%-1.56%+58.84%+22.22% 317B
+1.34%+2.80%+39.13%-8.25% 72.79B
+0.43%+0.37%+37.46%+97.10% 9.91B
+2.42%-5.13%-3.90%-5.54% 8.16B
+2.76%+8.47%-26.39%-14.85% 4.51B
+0.40%+6.83%-34.64%+7.29% 3.94B
+2.46%+2.71%-17.02%+21.19% 3.71B
+8.46%+0.73%+24.99%+45.77% 2.73B
-0.19%-0.38%-2.51%-3.33% 2.24B
Average +1.53%+2.12%+49.18%+9.89% 42.56B
Weighted average by Cap. +1.07%-1.17%+51.38%+17.56%

Financials

2026 *2027 *
Net sales 460M 399M 371M 342M 645M 43.75B 652M 4.37B 1.71B 21.89B 1.73B 1.69B 72.5B 478M 414M 386M 355M 671M 45.48B 678M 4.54B 1.78B 22.76B 1.8B 1.76B 75.37B
Net income 182M 157M 147M 135M 255M 17.27B 257M 1.72B 676M 8.64B 682M 667M 28.61B 210M 182M 169M 156M 294M 19.96B 297M 1.99B 781M 9.98B 788M 771M 33.07B
Net Debt - -
Logo Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Employees
100
Date Price Change Volume
05/08/26 US$4.150 -3.71% 2,209,855
04/08/26 US$4.310 -2.49% 5,768,302
03/08/26 US$4.420 +4.49% 3,818,188
31/07/26 US$4.230 +13.40% 3,583,359
30/07/26 US$3.730 +4.78% 1,299,350
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.150USD
Average target price
6.350USD
Spread / Average Target
+53.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IRWD Stock